newsonline24

The new feature digitizes and centralizes the entire site feasibility process, replacing traditional paper-based workflows with an integrated digital platform. This advancement enables sponsors to distribute study information, collect site responses, and evaluate site suitability within a single, unified system.

"Clinical trial site selection has historically been a major bottleneck in trial initiation, often leading to delays and increased costs," said Jill Tufano, President at EvidentIQ, LLC . "Our new Site Feasibility feature revolutionizes this process, offering a digital solution that significantly reduces administrative burden while improving decision-making quality."

Key features of the Clindex Site Feasibility solution include: 

• Digital feasibility questionnaires that eliminate paper-based processes 
• Comprehensive sponsor evaluation and site selection tools 
• Seamless workflow integration from feasibility to site activation 
• Centralized site database for future study reference 
• Complete audit trail ensuring regulatory compliance 

The platform maintains the highest standards of data security and regulatory compliance, including GCP and GDPR requirements, through encrypted data storage and role-based access controls. Its scalable architecture supports trials of any size, from single-site studies to complex multi-center trials.

"We’ve built this feature with both sponsors and sites in mind," added Philip Jorgensen,Senior Director, R&D Clindex. "The integration with our existing EDC, CTMS, and eTMF functionalities creates a seamless experience that saves time, reduces errors, and ultimately accelerates the path to trial initiation."

The Clindex Site Feasibility feature is available immediately as part of the Clindex eClinical platform. For more information about the feature and its capabilities, please visit www.clindex.com or contact jill.tufano@evidentiq.com